Page 417«..1020..416417418419..430440..»

If the menopause movement is to be truly revolutionary, it needs to include women with cancer – iNews

Posted: June 4, 2022 at 1:56 am

Theres a menopause revolution afoot and the three letters on everyones lips from Davina McCall to Sajid Javid are H, R, T. But one group missing from many of these discussions is cancer patients and, for many of them, hormone replacement therapy isnt a straightforward option. If this powerful patient movement is to be truly revolutionary, it must also find a way to include those going through the menopause alongside cancer.

Amy Meadows, a 48-year-old campaigns manager, tells me she feels completely excluded by the focus on HRT within the mainstream menopause discussion. A year ago, she was diagnosed with breast cancer after finding a lump. After undergoing surgery, chemotherapy and radiotherapy, Amy is now having hormone therapy a treatment that induces a chemical menopause, suppressing the bodys natural hormones to prevent oestrogen sensitive cancers like hers from spreading or recurring.

As Amys oncologist warned her, this type of medical menopause can be a more brutal experience than going through perimenopause naturally, because of the sudden drop in oestrogen levels. The nature of Amys cancer also means that HRT isnt an option to ease her menopausal symptoms of hot flushes, night sweats and insomnia. I do really welcome the extra profile being given to menopause, but I feel excluded from the fast-growing club of vocal HRT advocates, she says.

Almost all my friends are on some form of HRT and reporting the positive impacts, both in terms of short-term symptom relief but also the longer-term protective impact against dementia, diabetes, osteoporosis and cardiovascular disease. Some of these potential risks are the same very ones that I am now at greater risk of because of my cancer treatment, so I also worry that Im missing out on those benefits, Amy adds.

Menopause after cancer treatment doesnt just affect those with breast and gynaecological cancers. It can be brought on by the disease itself, or as a result of surgical removal of the ovaries, hormone therapy, chemo or radiotherapy. For example, radiotherapy to treat cancers in the pelvic area like bowel cancer can cause either temporary or permanent damage to the ovaries, inducing a medical menopause. HRT usually isnt recommended for anyone with a hormone-related cancer, most notably oestrogen receptor (ER) positive breast cancers, although topical oestrogen can be used to treat symptoms like vaginal dryness.

Even for those cancer patients who can take HRT, theres a much bigger conversation that needs to take place. Charity Trekstock, which supports young adults with cancer across the UK, runs a six-week Navigating Menopause programme and have found that 44 per cent of participants hadnt been told about early menopause by their oncology teams. 42 per cent of those who took part in the programme said they didnt get support when they sought help with their symptoms, and 88 per cent found their last doctors appointment on the subject unhelpful.

For young cancer patients, who may be going through menopause a decade or two earlier than they would have done naturally, its also a seriously isolating experience. Eighty per cent of people told us theyd never met another young person whod been through cancer and the menopause, so our programme isnt just about giving people the information and leaving them to it, its about sharing stories, empowering one another, and creating communities so people feel less alone, says Trekstocks Health Programmes and Engagement Lead Jemima Reynolds, who used her background in healthcare to co-create the programme alongside 43-year-old yoga teacher, menopause guide and patient advocate Dani Binnington.

A quality standard published by the National Institute of Health and Care Excellence (NICE) states that patients who are likely to go through menopause as a result of medical or surgical treatment should be made aware of this long-term after effect and its symptoms. In reality though, Jemima adds: Were finding time and time again that people arent told and, [even if they are told at their initial diagnosis] it isnt revisited.

Dani went through a temporary menopause during treatment for breast cancer in her 30s but at the time had no idea thats what it was. My periods stopped for a while when I was going through chemo, but I just thought all my symptoms were cancer or treatment related. I was poorly educated in terms of my biology and it wasnt until three years ago that I realised Id been in the menopause, she explains.

When Dani later found out she was a carrier of the BRCA gene mutation which increases the risk of both breast and ovarian cancers she made the decision to have a double mastectomy and an oophorectomy (surgery to remove her ovaries), with the latter putting her into an immediate surgical menopause.

This time, though, she was more clued up. I actually cancelled my oophorectomy twice because my appointment with the menopause specialist hadnt come through yet, and I knew I needed to speak to them before anyone touched my ovaries. This was six years after my cancer diagnosis and Id learned so much that I was a really good advocate for myself; I knew about my choices and what my options were, she explains.

Dani did opt for HRT, based on the fact she was more than five years on from her diagnosis, had already had a double mastectomy and had a type of breast cancer that wasnt hormonally driven. But she and Jemima are clear that cancer patients, regardless of their individual risks and treatment choices, need a far more nuanced conversation about the impact of cancer and the menopause on their lives. Theyre coping with the emotional trauma of going through cancer, with cancer-related fatigue, with body image changes, with all these costs to their mental and physical health, which are compounded by menopause. The onus shouldnt be on them to do the research and find out whats going on like Dani did. We need to equip them with the tools to not just survive cancer but thrive, Jemima says.

For this group that conversation must move beyond HRT and focus on overall health and wellbeing. We need some recognition that HRT is not the silver bullet everyone thinks it is. There are medical and non-medical alternatives to tackle menopausal symptoms, and these all need to be coupled with lifestyle factors like nutrition and exercise, Jemima says.

Weight-bearing exercise, she adds, is hugely important for post-menopausal bone health, as well as improving mood and cancer-related fatigue, both of which are often made worse by the menopause. Similarly, antidepressants which arent generally considered a first-line treatment for menopausal symptoms can be a great alternative to HRT when it comes to tackling not only mood changes but also physical symptoms like hot flushes.

Essentially, Dani adds, we need an acknowledgement that mainstream menopause advice doesnt necessarily apply to everyone. Much of this change will come from greater training and awareness for healthcare professionals within oncology and, in this sense, she says, its not too dissimilar to the mainstream menopause conversation. Theres a campaign for more GPs to go on specialist menopause courses; we also need more training for cancer nurses and oncologists. Its just an extension of the wider conversation thats going on anyway.

For patients too, there needs to be a much broader, more nuanced conversation about how menopause affects different people young and old, with and without cancer, on and off HRT. Menopause can be an isolating enough journey without being made to feel like an outsider, and this revolution must leave no one behind.

Read more here:
If the menopause movement is to be truly revolutionary, it needs to include women with cancer - iNews

Posted in Hormone Replacement Therapy | Comments Off on If the menopause movement is to be truly revolutionary, it needs to include women with cancer – iNews

Finding the "Sweet Spot": Thyroid Hormone Treatment and Cardiovascular Disease – Endocrinology Network

Posted: June 4, 2022 at 1:56 am

This article was originally published on PracticalCardiology.com.

Although it has long been known that thyroid hormone levels are linked to cardiovascular (CV) regulation and that hyper- and hypo-thyroid states are detrimental to CV health, less is known about how the intensity of thyroid hormone therapy affects CV risk and mortality.

In a recent study, investigators sought to evaluate the association between thyroid replacement intensity and cardiovascular mortality by examining a large pool of data from the Veterans Health Administration database.

Josh Evron, MD, and colleagues looked at 705,307 adults who received thyroid replacement therapy.3 They found that 10.8% of those patients died of cardiovascular causes.3 Thyrotropin and Free T4 levels were gathered for all patients in the study to determine if therapy led to exogenous hypo-, euthyroid, or hyperthyroid conditions. The authors used regression modeling to produce survival analyses with cardiovascular mortality from myocardial infarction, heart failure, or stroke representing the primary outcomes studied.

The results clearly showed that patients with exogenous hyperthyroidism (thyrotropin levels <0.1 mIU/L) and those with exogenous hypothyroidism (thyrotropin levels >-20mIU/L) had increased risk of cardiovascular mortality when compared to patients who remained euthyroid.3 The association between exogenous hypo- and hyper-thyroid states and mortality increase with higher or lower thyrotropin levels in the hypo- and hyper-thyroid ranges.3

This study provides a unique perspective looking at cardiovascular risk based on a very common treatment, thyroid replacement therapy. When prescribing a replacement therapy, the goal of treatment is to achieve a normal level in vivo of whatever hormone you are replacing. This is not as easy as it seems.

Arriving at the appropriate dose takes time and requires frequent measurements of thyrotropin and free thyroxine levels. Even during stable therapy patient factors may change the response, absorption, and metabolism of thyroid hormone. Thus, the intensity of treatment the authors are talking about is a constantly moving target.

The results of this study highlight the importance of regular testing and a willingness among clinicians to put in the work. The authors found that allowing thyroid replacement therapy to fall short or overshoot has real consequences in the form of increased cardiovascular mortality.3

This means lives are at stake. This is the essence of a modifiable risk factor. Only, in this case, the modification is not a behavior the patient exhibits but one the clinician is responsible for. The authors state that variability in free T4 levels and thyroid hormone dosage adjustment are inevitable and thus agree with my assertion that regular monitoring and small targeted adjustments are essential parts of not only good thyroid care but also cardiovascular risk mitigation.3

These results and conclusions are underscored by the fact that cardiovascular disease is the leading cause of death in the United States. Even though this was an observational study, the results are robust.

An important feature of these results was the linear relationship up and down between the extent of hypo- or hyperthyroid intensity and CV risk. This gives clinicians some room to work while at the same time placing guard rails and warning signs on the limits of acceptability where over and undertreating are concerned.

More work is needed. While the authors have identified an area where we as clinicians can improve, they have also brought up a few new questions. It needs to be determined if there are sex differences in this effect. Further, the degree to which comorbidities were managed was not examined in this study. It is clear however, that tighter observation, monitoring, and intervention are in order with regards to thyroid replacement therapy.

References:

Here is the original post:
Finding the "Sweet Spot": Thyroid Hormone Treatment and Cardiovascular Disease - Endocrinology Network

Posted in Hormone Replacement Therapy | Comments Off on Finding the "Sweet Spot": Thyroid Hormone Treatment and Cardiovascular Disease – Endocrinology Network

The Very Peri Summit Resource Centre: Hormone Replacement Therapy with Dr Yasmin Tan. – Mamamia

Posted: June 4, 2022 at 1:56 am

Dr Yasmin Tan is a Sydney gynaecologist, laparoscopic surgeon and womens ultrasound specialist. She works at the Womens Health and Research Institute of Australia (WHRIA) and at the Royal Hospital for Women. She is a Clinical Lecturer with The Universityof Sydney Northern Clinical School, Discipline of Obstetrics, Gynaecology & Neonatology.

In this session, we learn what exactly HRT is, whether it is safe and if it could help you.

Here's what we learned from Dr Yasmin Tan's session:

Hormone Replacement Therapy (HRT) is steeped in misinformation.

And that's a problem, because it's also one of the most effective methods for coping with many of the debilitating symptoms of perimenopause.

"HRT is any medication with female hormone in it, so it contains estrogen. That's the main hormone which we are trying to give back to the body because it's decided to make less of it, and as time goes by no estrogen," Dr Yasmin says.

"The second hormone we give usually with HRT is progesterone. And we need that for women who still have a uterus. The uterus is really an important organ that we have to protect with HRT because the lining of the uterus can thicken up if you just giveit estrogen alone."

HRT is used to relieve uncomfortable symptoms of perimenopause like hot flushes, mood swings, concentration issues, sleep problems and vaginal dryness.

There is a misconception that HRT is linked to breast cancer due to a study conducted over 20 years ago as Dr Yasmin explains.

"I think what this really stems from a big study that happened over 20 years ago called the Women's Health Initiative study.

"There are a lot of flaws with this study and we recognise this now. They were using very out of date, synthetic hormones, which we don't use anymore.

"The estrogen they were using was made from pregnant bears urine. So we don't use that anymore.

"And they also tried it in women of all age groups so the women were average ages around 65. That's not really our target age range for treatment.

"So they found that there was an increased risk of breast cancer and they touted this to the media and it was sold in a very catastrophic way.

Read this article:
The Very Peri Summit Resource Centre: Hormone Replacement Therapy with Dr Yasmin Tan. - Mamamia

Posted in Hormone Replacement Therapy | Comments Off on The Very Peri Summit Resource Centre: Hormone Replacement Therapy with Dr Yasmin Tan. – Mamamia

Rethinking Identity and Testosterone in Imagine a Body – The New Yorker

Posted: June 4, 2022 at 1:56 am

In one section of Connor Lee OKeefes short documentary Imagine a Body, a film in which transmasculine people discuss their varied experiences of taking testosterone in order to medically transition, we see the construction of a birdhouse: there are closeups of a nail being hammered, a sharp edge sanded down, a screw twisted into wood. In a voice-over, one of the interviewees hints at the relationship between the imagery and the films subject matter. Theres this idea in sculpting where you take a chunk of wood, and you carve away whats not supposed to be there to reveal what should have been there the whole time, he says. He compares that idea to the feelings he had when he started on testosterone: Suddenly, its, like, Oh, theres the person that was supposed to be there this whole time.

OKeefe was inspired to make the film when, after taking testosterone for many years, he increased his dosage. Experiencing a new set of changes, he began to conceive of transition as a nonlinear process, an evolution rather than a clear-cut before and after. He decided that he wanted to create something that was exploratory in its approach, guided by subjects with a diverse array of notions about their own genders. He completed interviews with seven people, each one at least two hours long, and then sifted through the hours of recordings for the most interesting moments. A noticeable pattern that emerged was the way hormone-replacement therapy had defied expectations. Everyone came in with one idea of what gender was and what their relationship to it was, and kind of grew into a different place, he told me.

How can we talk about transition in a less medicalized way? OKeefe wondered. The film does not attempt to show the concrete effects of transition, and dispenses with the talking-head format that is customary for interview-driven documentaries; it favors, instead, an abstract approach. Imagine a Body takes a physical experience and, rather than render it in clinical terms, suggests its complex affective landscape. Interview responses are paired with images, a combination of picturesque landscapes, dynamic rotoscope illustrations, and scenes that subtly convey the changes caused by transition: shaving, or setting off on a run among the trees. With its surprising turns from one voice-over to the next, the film presents a swirling, evocative variety of insights. Once I started passing just by speaking, it completely changed my world, one subject says. Moments later, another says, I hated my voice as a child. And I cant say I ever stopped hating my voice. Like, I still do. In delving into the intricacies of trans experiences, Imagine a Body does not reduce the evolution of identity to a simple journey from problem to solution. The objective is not merely the treatment of a condition but the capacity to experience a more rich, full spectrum of life.

Originally posted here:
Rethinking Identity and Testosterone in Imagine a Body - The New Yorker

Posted in Hormone Replacement Therapy | Comments Off on Rethinking Identity and Testosterone in Imagine a Body – The New Yorker

Postmenopausal Years Are Creative and Satisfying for Women – Oprah Mag

Posted: June 4, 2022 at 1:56 am

The term postmenopausal implies that the rest of life after what our grandmothers called the change is nothing but an afterthought. Clinical psychologist Louann Brizendine, MD, founder of UCSFs Womens Mood and Hormone Clinic and author of the bestsellers The Female Brain and The Male Brain begs to differ.

To hear her tell it, that stagewhich can be a full half of a womans lifeis more like aprs-ski: the luxurious reward after all the drama of hurtling down hormonal peaks and valleys. In her new book, The Upgrade: How the Female Brain Gets Stronger and Better in Midlife and Beyond, she renames and reclaims the M word, which she calls the Transition and recasts the years after as the Upgrade that gives the book its title.

Rest assured that the good doctor is not just advising women to look on the bright side and think positively about acquiring the wisdom and experience that come with age. (Although shes all for that.) She also explains the science behind the Upgrade, how after the Transition, were equipped with our Brain 2.0, which is less foggy, calmer, steadier, and primed to be more focused, creative, and happy than ever before. Then she tells readers how to make the most of that new functionality. We interrupted her Upgrade to ask her a few questions.

Why dont you use the terms menopause and postmenopause?

Perimenopause, menopause, postmenopause are a medical diagnosis, pharmaceutical words. Its a very narrow shaping of whats happening to us in our lives. I call it a below-the-waist-view of the uterus, the bleeding, but its not about whats going on in the brain. The idea that its a transition and an upgrade is multifaceted, more of what I call the whole-woman approach to the stage of life that were in. And the fact that you have a whole new breath of life for this second half of life, thats the concept I want to get across.

Now 23% Off

You write that, post-Transition, our brains are primed for an Upgrade. Why is that, neurologically speaking?

When youre menstruating, estrogen going up in those first two weeks of your cycle starts to make all of these connections in the area of the brain called the hippocampus. And then when the progesterone starts to come in after ovulation, weeks three and four, it tears down all of those connections. That cycle goes on month after month after month, and it has all kinds of pushes and pulls for our behavior. We know from behavioral studies that three or four days before ovulation, we become more talkative, and toward the end of the cycle, we become more emotionalI call it the crying-over-dog-food-commercials stage. Whats going on in our brain is the building up of the circuitry and tearing it down and building it up and tearing it down. That stops after the Transition. Thats why I call it the Upgrade, because it gives you this incredible stability.

What if you take hormone replacement therapy?

If you do, youre getting a steady amount of hormones; theyre not coming in waves. As the waves of the hormones stop and get calmer, whether you take HRT or you dont, your hormones are going to be steady. That remakes the circuitry in your brain in a more stable, calm fashion.

You also talk in the book about how neurohormones, pre-Transition and during the Transition, can push us to be self-critical, and to feel the need to please people or win their approval.

The whole fertility phase of our lives as women is a very deep, deep hormonal push to cause behavior to make us try to be more attractive, so were able to procreate better. Its not something thats right in the front of your mind; its a kind of subconscious drive to procreate in the back of our brains.

Thats not happening so much after the Transition. So were not pushing ourselves to be complete people pleasers. We still dont want to be kicked out of our family or excluded from our community by becoming a total be-atch. Thats not what I recommend. But, subconsciously, because of the neuro changes in our brain, were able to speak our minds more without the fear that we once had, now that the subconscious pressure to procreate isnt going on.

In the book, you explain how if we know whats going on in our brain, we can use that knowledge to our advantage.

We just keep learning more about the brain. For example, we always called the cerebellum, the two little bumps in the back of your brain, the sports brain because it helps with your balance. But in 2018, studies showed that it also sends all of this feedback to the rest of the brain, and it helps to assess emotions and thinking. We do that in the front part of our brain, but if we get a little bit off, our cerebellum helps us with our emotional balance. It helps us with our thinking balance. Itll help slightly correct if you get too far off center. And if you choose an activity, like yoga or barre class, that helps with your balance, it will stimulate that area of the brain.

You offer a lot of actionable tips in the book for making the most of the Upgrade by using science-backed practices. What are some of your favorites?

When I wake up in the morning, I wiggle my toes and I smile. Wiggling your toes activates the sciatic, the longest nerve in your body, and stimulates all the way up into your brain, your cerebellum, your whole motor strip. And studies show that when you smile, the smiling muscles actually feed back into your brain to tell you that youre happy, so you could increase your feeling of happiness just by smiling at yourself.

I also do butt squeezes throughout the day, because in a study where they tested cognition in 80-year-old women, those women with the best cognition also had the strongest leg strength. When your muscles are strong or when youre moving your muscles, its feeding back into your brain all the way from your cerebellum to the rest of your motor area, telling you that youre alive and that youre okay. And one of the biggest muscles in our body is the glutes, our butt muscles. So if you want to improve some of your cognition, just keep doing butt squeezes during the day when you sit down or as you brush your teeth.

In another cool study, done 2010 at Harvard, they would text people and say, What are you doing now? And then theyd have to do a happiness scale. Those people that were just daydreaming, who had a wandering mind, reported that they were not happy, but the same person, when they were engaged in what they were doing when they got the text, said they were happy. If you let your mind wander, it can run into the hamster wheel of worry or other bad places. So you want to take the steering wheel of your mind and steer it toward engagement.

So, when the chatter of all the hormonal waves dies down in your brain, you get to choose what to fill it with, and you want to choose wisely?

Yes. Thats why I wrote this book, for women to just grab the steering wheel of their life, to move forward in a way that makes them happier, with more joy and serenity. As women go through this stage, its important to know that this is coming, so then you can seize that stability in the brain, and feel empowered by this idea that you have an upgrade, a chance to do something new. You have to feel delighted about your life in this next stage, because its really great. Theres a technical term, the positivity effect, thats been studied for the last 40 years at Stanford and other places that shows that with each decade of your life, you get happier. That goes along with the Upgradepeople just get happier each decade of their life. I think thats a really important message.

This content is imported from OpenWeb. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

More:
Postmenopausal Years Are Creative and Satisfying for Women - Oprah Mag

Posted in Hormone Replacement Therapy | Comments Off on Postmenopausal Years Are Creative and Satisfying for Women – Oprah Mag

Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal – The…

Posted: June 4, 2022 at 1:55 am

Stem Cells Market: A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Stem Cells Market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Stem Cells research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

To Understand Business Strategies, Request For a Sample Report at:https://www.industrydataanalytics.com/reports/stem-cells-market/inquiry?Mode=A130

Key players in the global Stem Cells market covered in are:

CCBC, Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, U.S), Merck KGaA, Cynata Therapeutics (Victoria, Australia), AMSBIO (Abingdon, United Kingdom)

Market Segmentation

Segmentation by type:

Umbilical Cord Blood Stem Cell

Embryonic Stem Cell

Adult Stem Cell

Others

Segmentation by application:

Diseases Therapy

Healthcare

Others

The study will assist both existing and new aspirants in the Stem Cells market in establishing and investigating the industrys needs, market size, and competition, based on data collected from multiple research methodologies as well as trustworthy data sources. Reports provide graphical estimates for the coming years based on recent events and historical data. Researchers employed top-down and bottom-up approaches to collect data and estimate income for all regions of the Stem Cells market.

Regional Analysis for Stem Cells Market:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

The objective of the study is to define the Stem Cells market sizes of different segments and countries in previous years and to forecast the values for the next five years. The report is designed to incorporate both qualified qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about crucial aspects such as drivers and restraining factors that will define the future growth of the Stem Cells market.

Detailed TOC of Global Stem Cells Market @https://www.industrydataanalytics.com/reports/stem-cells-market?Mode=A130

Reasons to buy

Table of Contents:

Customization of the Report:

IndustryDataAnalytics provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

IndustryDataAnalytics is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resources, automobile, IT, technology and media, food and beverages, and consumer goods, among others.

Head of Sales: Mr. Hon Irfan Tamboli

+1 (704) 266-3234 | contact@industrydataanalytics.com

Here is the original post:
Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal - The...

Posted in Massachusetts Stem Cells | Comments Off on Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal – The…

Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD – OncLive

Posted: June 4, 2022 at 1:55 am

Novel agents seek to improve and expand the efficacy of the current standard of care for patients with acute graft-vs-host disease, specifically those with high-risk disease.

High-dose systemic steroid administration has limited durability for patients who develop acute graft-vs-host disease (aGVHD). Novel agents seek to improve and expand the efficacy of the current standard of care for patients, specifically those with high-risk disease.

We all want to find new agents that are more effective as frontline therapy for [patients with] aGVHD, said Corey S. Cutler, MD, MPH, FRCPC, in an interview with OncologyLive. Even with a very potent anti-inflammatory [such as] steroids, only 50% of our patients are getting a real benefit. Anything that we could use in the frontline setting that will help improve those response rates certainly seems like it will be a very welcome addition to our armamentarium.

A complication of allogeneic hematopoietic stem cell transplant, aGVHD occurs in approximately 50% of patients who undergo this procedure. Onset of aGVHD usually occurs within 100 days of transplant and involves the skin, liver, and gastrointestinal (GI) tracts. Initiation of high-dose corticosteroids is the current standard of care; however, nearly half of patients become refractory to treatment.1

Efficacy data for high-dose corticosteroids alone have demonstrated inferior response rates among individuals with high-risk aGVHD vs those with standard aGVHD. For example, a retrospective analysis stratified patients by risk status and reported that the overall response rate at day 28 after treatment was 44% (95% CI, 38%-50%) among 269 patients with high-risk aGVHD vs 68% (95% CI, 66%-70%) among 1454 patients with standard-risk aGVHD.2 The complete response rates (CR) were 27% (95% CI, 22%-33%) and 48% (95% CI, 45%-51%), respectively with partial response (PR) of 16% (95% CI, 12%-21%) and 21% (95% CI, 19%-23%).2

To address this unmet need, investigators have initiated the phase 3 pivotal EQUATOR trial (NCT05263999), which will evaluate the novel monoclonal antibody, itolizumab (Alzumab), in combination with standard-of-care corticosteroids vs placebo in patients with aGVHD.3

We know that CD6 is a costimulatory receptor found on activated CD4 and CD8 T cells. We also know that the ligand called ALCAM, is expressed on antigen-presenting cells, as well as the inflamed tissues in the skin and GI tract. Since those [receptors] are [present in] the target organs of aGVHD, preventing these T cells from getting to their target makes a lot of sense [and] itolizumab is a promising compound, said Cutler, who is medical director of the Adult Stem Cell Transplantation Program, director of clinical research, stem cell transplantation, and director of the Stem Cell Transplantation Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts.

Itolizumab, a first-in-class anti-CD6 monoclonal antibody targets the CD6activated leukocyte cell adhesion molecule (ALCAM) pathway, which modulates the activity of T cells that drive immunoinflammatory diseases, and has demonstrated early activity as a first-line therapy for patients with high-risk aGVHD in the phase 1/2 EQUATE trial (NCT03763318).4,5

Itolizumab is a monoclonal antibody that binds to the CD6 [protein], which is expressed on immune effector, or proinflammatory T cells; it is part of the costimulation pathway, John Koreth, MBBS, DPhil, said in an interview with OncologyLive. Interestingly, [itolizumab] is slightly different [from other agents] in that it does not delete or kill the cells that it binds to, but results [in the] shedding of CD6 from the surface of the cells, and switches [these cells] from a CD6-high to a -low state. By doing so, it appears to switch them from a proinflammatory immune effector cell to a less inflammatory, regulatory T-cell phenotype. That is part of the mechanism [of action of the agent,] and interfering with the CD6 costimulation is another way of blunting the inappropriate immune activity that we believe is part of the underlying pathology in GVHD, explained Koreth, who is the director of Translation Research and Stem Cell Transplantation and professor of medicine at Harvard Medical School.

The EQUATE trial comprised 2 parts: a 3 + 3 dose-escalation portion and a randomized double-blind phase.6 The phase 1b/2 trial tested 3 dose levels0.4, 0.8, and 1.6 mg/kg, Cutler said. According to our pharmacokinetic and pharmacodynamic studies, the 0.4-mg/kg dose was probably insufficient, but there was really no advantage of the 1.6-mg/kg dose [compared with] 0.8 mg/kg.

At the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation, investigators reported updated data from the EQUATE study. At day 15 of treatment, the complete response rate was 52% among the 20 patients who received itolizumab and was maintained through day 29. The overall response rate was also assessed at days 15 and 29 and was reported at 74% and 65%, respectively. At day 29, 72% of patients were still receiving treatment with corticosteroids.5

End of treatment was considered day 57, at which time 50% of patients had durable response. In a follow-up analysis, 45% of patients had an ongoing response at day 169 and the nonrelapse mortality rate was 35% with an estimated overall survival rate of 65%.5

An observational end point of the EQUATE study was the reduction of corticosteroid use, which investigators reported that patients either maintained steroid reduction from day 29 and/or continued tapering through day 169. These are the patients who we are concerned would not be likely to achieve a good response to the standard of care, which is corticosteroids alone, Koreth said. No FDA-approved therapies [are available] for this indication, but we do have patients who are routinely treated with steroids across the world.

In terms of safety, at the interim analysis investigators reported that all participants experienced at least 1 adverse effect (AE), with serious AEs reported among 65% of patients. A concern for this patient population is infection, which was reported among 43% of participants.5 I want to underscore that this is a sick population; these are patients with acute involvement, typically of the lower intestinal tract, Koreth said noting that individuals often present with ulceration of the intestinal epithelium, risk of bleeding, and diarrhea.

We expect high rates of severe adverse effects [AEs] based on the nature of this illness. [That being said, we] did see infections [with the agent, although] the rates were not dramatically different than what we would have expected. Although there were rates of significant AEs, including a significant rate of infections, that did not differ from what we would have expected a priori going into the study, given the illness of these patients, Koreth said.

Building on the data from EQUATE, Koreth highlighted the data used to inform the protocol for the phase 3 design. When [investigators] looked the specific subset of patients who were treated within 3 days of the onset of steroids, which is the trial design for the [phase 3] study, the CR rate was [61%] and the ORR was [67%]again, this is across all dose levels, Koreth said. [These findings] did suggest a response rate that was substantial. [It is important to remember, however, that this] was an uncontrolled analysis, which is why the follow-up [phase 3] study is so critical.

EQUATOR will enroll approximately 200 patients with grade 3/4 aGVHD, or grade 2 aGVHD with lower GI involvement, a population of patients at a higher risk to develop steroid refractory disease, Cutler said. The randomized trial is an extension of the phase 1b/2 study [and] is the proof phase [in which] that we will [use] the preliminary data that weve gathered [to meet] the main objective [of the study]: to determine whether the addition of itolizumab to corticosteroids is in fact better than steroids alone for the initial therapy of aGVHD, Cutler said.

EQUATOR will enroll approximately 200 patients with grade 3/4 aGVHD, or grade 2 aGVHD with lower GI involvement, a population of patients at a higher risk to develop steroid refractory disease, Cutler said. Staging will be determined using the Mount Sinai Acute GVHD International Consortium (MAGIC) grading criteria.3 Grade 3 disease is defined as stage II/III liver and/or stage II/III lower GI involvement with stage 0-III skin and/or stage 0/I upper GI involvement. Grade 4 disease is defined as stage IV skin, liver, or lower GI involvement with stage 0/I upper GI involvement.7 Additionally, patients must be 12 years or older and have undergone initial allogenic hematopoietic stem cell transplant, have evidenced of myeloid engraftment.3

Patients will be randomly assigned to receive itolizumab within 3 days of the first administration of high-dose corticosteroids or placebo. Based on the data from EQUATE, itolizumab administered at 0.8 mg/kg once every 2 weeks for 6 doses will be used in EQUATOR following an initial dose of 1.6 mg/kg.3 Steroid tapering is recommended.

Were [evaluating] to itolizumab in the frontline setting for [patients with] aGVHD [in an attempt to] both increase the response rate to initial therapy with corticosteroids, as well as prevent patients from having early relapses when we start tapering their corticosteroids, Cutler said. Steroids are very toxic in the acute setting and anything we can do to minimize our patients exposure to this class of drugs will be beneficial in the long term, as long as response rates are not compromised by giving lower doses of steroids.

The primary end point is early disease response evaluated at 29 days after initiation of treatment. The secondary objectives include durability of response, corticosteroid use, survival outcomes, and chronic GVHD incidence.

[Itolizumab] could be a potential game changer, Koreth said. If patients have a therapy that can rapidly induce a CR that is durable, allows us to taper steroids, and improves survival, then that would be the new standard of care for these patients, who, at this point, have a very significant unmet medical need. [This] is a rigorous trial design, and I hope, if successful, there will be a straight path to approval of the medication so that patients in need can receive it.

Go here to see the original:
Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD - OncLive

Posted in Massachusetts Stem Cells | Comments Off on Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD – OncLive

Ghost heart grown with scaffolding from a pig’s organ and patients cells – New York Post

Posted: June 4, 2022 at 1:52 am

A ghost heart grown with scaffolding from a pigs organ and human cells may soon be used in human transplants, experts say.

A molecular biologist said that after seeing heart cells beat in unison in a petri dish, she can truly imagine building a personalized human heart.

Doris Taylor, director of regenerative medicine research at Texas Heart Institute, said that by using a patients own tissues, they were able to create a viable option with pig cells that the body will not reject.

It actually changed my life, Taylor toldCNN. I said to myself, Oh my gosh, thats life. I wanted to figure out the how and why, and re-create that to save lives.

Taylor said the innovative replacement could potentially become a planned procedure rather than a last-minute surgery.

That reduces your risk by eliminating the need for [antirejection] drugs, by using your own cells to build that heart it reduces the cost .. and you arent in the hospital as often so it improves your quality of life.

Taylor also presented a robot that was taught to administer the human stem cells into the ghost heart in a sterile environment.

The biologist showed a video of the translucent manufactured heart turning pink after it was injected.

Its the first shot at truly curing the number one killer of men, women, and children worldwide heart disease. And then I want to make it available to everyone, the scientist excitedly shared.

CEO of Advanced Solution Michael Golway applauded Taylors work and tenacity in the years-long project.

At any point, Dr. Taylor could have easily said Im done, this just isnt going to work,' Golway told CNN.

But she persisted for years, fighting setbacks to find the right type of cells in the right quantities and right conditions to enable those cells to be happy and grow.

Taylor first came interested in growing hearts when she worked on a team in 1998 at Duke University.

The team injected cells into arabbits failed heartand created new heart muscle.

However, whenever she attempted to translate the success onto human biology it was hit or miss.

We were putting cells into damaged or scarred regions of the heart and hoping that would overcome the existing damage, Taylor said.

I started thinking: What if we could get rid of that bad environment and rebuild the house?

In 2008, Taylor found real success when she and the team at the University of Minnesota rid a rats heart of cells and started working with the translucent skeleton left behind.

After this breakthrough, she moved into pigs hearts because of their anatomical similarity to humans.

Im just humbled and privileged to do this work, and proud of where we are, Taylor said.

The technology is ready. I hope everyone is going to be along with us for the ride because this is game-changing.

This story originally appeared on The Sun and was reproduced here with permission.

See the rest here:
Ghost heart grown with scaffolding from a pig's organ and patients cells - New York Post

Posted in Regenerative Medicine | Comments Off on Ghost heart grown with scaffolding from a pig’s organ and patients cells – New York Post

Overcoming the Challenges of Cell and Gene Therapy Facilities – Genetic Engineering & Biotechnology News

Posted: June 4, 2022 at 1:52 am

By Tom Piombino

For the cell and gene therapy (CGT) sector, recent years have been nothing less than phenomenal. For example, according to the Alliance for Regenerative Medicine, the sector has witnessed skyrocketing investment. The $7.5 billion raised in 2017 was more than tripled by the $22.7 billion raised in 2021.

Besides creating opportunities for CGT companies, such funding is creating a crunch for both real estate and talent. For example, in San Francisco, more than half a billion square feet of manufacturing space has been acquired by CGT companies in the past year. In Philadelphia, where academia is generating intellectual property in the CGT space at a torrid pace, more than one million square feet of new laboratory space is in development.

In North Carolinas Research Triangle regionwhere vacancy rates have kept per-square-foot development in the $30s range (as opposed to downtown Bostons $100/square foot)the competition for resources has placed a premium on selection and planning, as CGT programs shift from R&D, which occurs in science clusters, to manufacturing, which occurs in attractive suburban markets.

This shift is a huge challenge for CGT companies. The transition from research and preclinical development to process development and clinical manufacturing is rough. Some stakeholders underestimate the difficulties of taking their businesses to the manufacturing phase, and they end up treading water in a sea of limited options. While the pandemic significantly impacted the office market, many of the available and proposed building conversions cannot provide the rigor or meet the cost expectations of a manufacturing facility.

Site selection in todays market goes beyond engineering and real estate. It requires bringing knowledge and talent to appreciate the perspectives of more diverse workforces and company cultures while sustaining market growth, promotion, and compliance. From an organizations project inception, unity of the resources early in a planning process offers owners the perspectives needed to make the right decisions for their businesses while focusing on the big picture of bringing groundbreaking therapies to market. All too often, these decisions are predicated on immediate needs (2 years out) or currently available resources, instead of a vision of technological progress (10 years out).

Site selection can be daunting for the most seasoned real estate professionals, and even more so for people whose expertise is outside of the field. Selecting an attractive siteone with the proper structural capacity, heights, utilities, workforce availability, access to transportation, access to parking, and amenitiescan quickly become an all-consuming task for an operating company. Additionally, predicting the needs and wants of a workforce in a transitionary state, post-pandemic, adds another dimension of complexity for peoples whose day job is attending to developing science.

Much like an engineering design process, the building out of early-stage GCT facilities requires a deliberate approach with input from experts whose knowledge in various fields benefits the project as a whole. It must start at the business case inception, utilizing a well-rounded team that can streamline the process and thoroughly explore solutions while addressing needs and challenges across the organization. While speed is incredibly important at this stage, attempts at seeing this inceptionary process as a transaction often result in a misrepresentation of the required outcome.

Using applied experience and several iterations, an experienced project team with an understanding of the business case can recognize trends, similarities, and the opportunities to quickly adapt the solutions that can be acted upon in weeks rather than months. If this approach is taken from the inception of a project, owners can realize considerable benefits and avoid distractions from their day jobs.

First, it brings into focus a clear multiyear plan addressing the operational needs of the organization: Who will need to be hired for research, quality control, manufacturing, maintenance, packaging, and shipping, among other positions? How can an organization build its culture during the growth period? What kinds of efficiencies are needed in the facility? What impact will the operational costs have on funding resources? How does residual value of the asset impact the investor appetite in a facility?

Second, it brings more value to the effort by helping owners explore costs and schedules from the outset. If owners begin months later, during conceptual design, they may belatedly discover that they could have been better positioned to seize growth opportunities.

Planning for companies in a fast-growth period can be daunting, especially in a real estate environment as competitive as the one that currently exists. Company leaders versed in other aspects of the business such as R&D may not have a sense of how much space will be needed in the long term, or of how much effort will be needed to ensure a space meets requirements such as staying up to code.

Onboarding the project team early on can be key to making a project successful because it streamlines the iterative process. By working closely with owners at the inception of the project, team members learn what works for organizations and what does not, building upon the plan as it progresses.

It also develops trust and confidencetwo elements that are especially valuable when the team needs to be flexible in the exploratory phase of project planning. Not only do these elements empower team members to present multiple options, including unconventional options, it gives them the space to learn from feedback and converge on the right solution.

When evaluating options, organizations have to focus on important factors for each element of the plan:

Site: This is about more than the location of the facility. The site plays a key role in meeting the organizations current goals and serves its future growth. With those near-term and long-term goals prioritized, the team can address details such as the need to include multi-floor manufacturing facilities or loading docks capable of accommodating particular types of vehicles.

Also, not to be overlooked in site selection is customer access. Ensuring that an organizations key audience can easily access these facilitieswhether they are in urban areas, which may present traffic and parking difficulties, or in smaller markets, which may not be as easily accessible by commercial transportationwill be a factor in the decision-making process.

Space: The rapid growth in the CGT market puts space at the forefront of planning for small companies. How big does a new facility need to be? What features will need to be included? Can the current building stock in a market serve an organizations needs, or will a greenfield development be required? Much of the real estate market is developer-driven rather than company-driven, which has both benefits and challenges.

In a developer-driven project, a facility may be fitted out to serve as a manufacturing nexus for cell therapies, gene therapies, and biologics. Alternatively, a facility may meet a particular manufacturing need, once the developer determines the appropriate scale reviews a few solutions. While there are few standard solutions that fit all CGT companies, by taking standard ideas and measuring the options to the needs, organizations can streamline the process by tailoring elements to their requirements.

Brand: More than being about aesthetics, a facilitys appearance has the ability to tell an organizations story, from its culture to its future plans. While a warehouse can serve a company like Amazon quite effectively, for growing CGT companies wanting to attract top talent and top funders, the impression that a facility presents impacts the mission of the company as well as how an organization can differentiate itself from other companies in a competitive marketplace.

Expectations: There are a lot of companies that can get derailed early on in the process, as their expectations can deviate from reality.

For owners coming out of institutions that are not well placed, moving to a central location might put them in greater proximity to talent. It also could come with significant extra costs in rent, construction, and operations. Rents within regions, not justbetween regions, can swing significantly.

However, organizations also must be honest when considering the costs. For example, is $22/square foot for rent in the suburbs more cost effective compared to $55/square foot near a city core if it means sacrificing the ability to recruit talented people who refuse to work in the suburbs?

In addition, with space at a premium, can an organization live with a real estate strategy that might require a stepped approach to growth? In the rapidly expanding CGT markets, many companies moving from research to trials to manufacturing have compromised on facilities that are too small or in the wrong location, putting growth strategies at risk.

The demands on CGT companies are different from those on other companies. Even as biopharma players have moved into the market, the competition has only increased the difficulty of coping with the markets growth.

The move from research to preclinical trials to clinical manufacturing is occurring at such a pace that it is leaving some companies waiting at a crossroads without a complete strategy on moving forward. By engaging technical and subject matter experts as part of a project team early in the process, organizational leaders can make decisions that will position their organizations for years of growth.

Tom Piombino (tpiombino@ipsdb.com) is managing director of the Americas for IPSIntegrated Project Services. For more information on the Inceptioneering process, please visit http://www.ipsdb.com/expertise/services/inceptioneering.

Link:
Overcoming the Challenges of Cell and Gene Therapy Facilities - Genetic Engineering & Biotechnology News

Posted in Regenerative Medicine | Comments Off on Overcoming the Challenges of Cell and Gene Therapy Facilities – Genetic Engineering & Biotechnology News

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple…

Posted: June 4, 2022 at 1:52 am

--100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors --

-- 22 of 31 (71%) evaluable patients reached CR/sCR --

-- 13 of 16 patients (81%) dosed more than 12 months ago reached CR/sCR; 8 (50%) with EMD; 9 (56%) remain in ongoing response with a median follow up of 17.7 months --

-- No cases of Grade 3 CRS and no delayed neurotoxicity or parkinsonian-like events observed at RP2D (n=25) --

-- Phase 2 pivotal study on track to initiate by YE 2022 --

-- Management to host live webcast event on Sunday, June 5, 2022, at 7:00 p.m. CDT to discuss new positive CART-ddBCMA data with a panel of clinician experts --

FOSTER CITY, Calif., June 3, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive clinical data from the ongoing Phase 1 expansion study of its novel, autologous, CART-ddBCMA therapy for the treatment of patients with relapsed or refractory multiple myeloma. The clinical results are being presented during an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Evaluable for efficacy and safety analysis were 31 patients, based on follow-up of at least one month, following treatment. These evaluable patients comprised the dose escalation cohorts for the first dose level (100 million CAR+ T cells, n=6), the second dose level (300 million CAR+T cells, n=6), and a dose expansion cohort at the recommended Phase 2 dose (RP2D) of 100 million CAR+T cells (n=19). All patients enrolled in the study have poor prognostic factors with 21 of 31 (68%) patients penta-refractory, 12 of 31 (39%) extramedullary disease (EMD), and all 31 patients having had at least three prior treatments.

The interim CART-ddBCMA clinical results (May 3, 2022 cutoff date) demonstrate deep and durable responses in patients with poor prognostic factors.

Matthew J. Frigault, M.D., CART-ddBCMA study investigator and Assistant Director of the Cellular Therapy Service at Mass General Cancer Center and Instructor at Harvard Medical School said, "The demand for clinically meaningful and safe CAR-T therapies outweighs what's currently available to multiple myeloma patients. It is encouraging to see these data continue to demonstrate deep responses and provide a benefit to patients. I look forward to enrolling patients in the Phase 2 pivotal study."

"We're excited by these long-term results, particularly given the challenging patient demographics, and believe these promising results reflect the potential for our lead program, CART-ddBCMA, to be a best-in-class treatment for patients with multiple myeloma," said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. "We believe there's a significant unmet need for cell therapies and we're committed to providing physicians with a safe and effective treatment option for multiple myeloma patients. We're honored to have our data presented at ASCO by Dr. Frigault and look forward to beginning enrollment in our Phase 2 pivotal study by the end of this year as the next step in the path towards regulatory approval."

The presentation can be accessed on the company's corporate website here.

Oral Presentation Details:

Title:Phase 1 Study of CART-ddBCMA in Relapsed or Refractory Multiple MyelomaSpeaker:Matthew J. Frigault, M.D., Assistant Director of the Cellular Therapy Service at Mass General Cancer Center, and Instructor at Harvard Medical SchoolSession Type/Title:Oral Abstract Session/Hematologic MalignanciesPlasma Cell DyscrasiaSession Date:Sunday, June 5, 2022Session Time: 8:00 a.m. 11:00 a.m. CDTLocation:McCormick Place Convention Center, Chicago, IllinoisAbstract Number:8003

Webcast Event:

Arcellx will host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, June 5, 2022, at 7:00 p.m. CDT. The event will be accessible from Arcellx's website atwww.arcellx.comin the Investors section. A replay of the webcast will be archived and available for 30 days following the event.

About Multiple Myeloma

Multiple Myeloma (MM) is a type of hematological cancer in which diseased plasma cells proliferate and accumulate in the bone marrow, crowding out healthy blood cells and causing bone lesions, loss of bone density, and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment, called a myeloma protein (M protein), causing kidney damage and impairing the patient's immune function. Multiple myeloma is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all hematological cancer cases and 20% of deaths due to hematological malignancies. The median age of patients at diagnosis is 69 years with one-third of patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple co-morbidities and toxicities that can quickly escalate and become life-endangering.

About CART-ddBCMA

CART-ddBCMA is Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma. CART-ddBCMA is currently in a Phase 1 study. Arcellx's proprietary binding domains are novel synthetic proteins designed to bind specific therapeutic targets. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration.

About Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.

Visitwww.arcellx.comfor more information.

Forward-looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part I, Item 1A (Risk Factors) of Arcellx's Annual Report on Form 10-K and in other reports, such as Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, that Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:Myesha LacyArcellx, Inc.[emailprotected]510-418-2412

Media ContactLaura Morgan Sam Brown Inc.[emailprotected] 951-333-9110

SOURCE Arcellx, Inc

Read the original here:
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple...

Posted in Regenerative Medicine | Comments Off on Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple…

Page 417«..1020..416417418419..430440..»